Leukaemic blasts differ from normal bone marrow mononuclear cells and CD34+ haemopoietic stem cells in their metabolism of cytosine arabinoside

被引:13
作者
Braess, J [1 ]
Wegendt, C
Feuring-Buske, M
Riggert, J
Kern, W
Hiddemann, W
Schleyer, E
机构
[1] Univ Munich, Klinikum Grosshadern, Med Clin 3, D-81377 Munich, Germany
[2] Univ Gottingen, Dept Haematol & Oncol, D-3400 Gottingen, Germany
[3] Univ Gottingen, Dept Transfus Med, D-3400 Gottingen, Germany
[4] Gustav Carus Univ, Dept Haematol & Oncol, Dresden, Germany
关键词
AraC metabolism; CD34(+) stem cells; AraCTP; AraUTP; AraCDP-choline;
D O I
10.1111/j.1365-2141.1999.01338.x
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Different metabolites of cytosine arabinoside (AraC) contribute to its cytotoxicity including incorporation of AraCTP into DNA, the incorporation of AraUMP into RNA, inhibition of polymerase alpha and beta (AraCMP/CTP), an impairment of repair mechanisms (AraCTP), alterations of phospholipid metabolism (AraCDP-choline), a direct membrane interaction (AraC), the alteration of signal transduction pathways (AraCDP-choline, AraCTP) and the induction of apoptosis. Since little is known about the potential differences in AraC metabolism between leukaemic blasts and normal haemopoietic progenitor cells, the formation of all known AraC metabolites was determined in bone marrow samples from patients with acute myeloid leukaemia (AML), healthy volunteers and specimens of cellsorted CD34(+) haemopoietic stem cells. Highly significant differences were found for phosphorylated AraC metabolites (AraCMP, -CDP, -CTP, AraUMP) between AML and normal mononuclear bone marrow (ng/10(7) cells respectively 1.30 v 2.66; 2.65 v 7.50; 33.68 v 99.0; 1.18 v 5.70). The highest differences were found for formation of AraCDP-choline (3.75 v 12.86) which might be relevant for the high efficacy of high-dose AraC regimens, In contrast, no differences were found in the deamination product AraU (2.01 v 2.91). Only minute amounts of phosphorylated AraU derivatives were detected, providing an explanation for the lacking contribution of AraU to cytosine arabinoside cytotoxicity. Results in normal CD34(+) haemopoietic stem cells did not differ significantly from normal bone marrow mononuclear cells and therefore justify their use as a surrogate in determining AraC-induced haematotoxicity. These data suggest a metabolic basis for the relative selectivity of AraC cytotoxicity for AML blasts and provide a means to determine the role of different metabolites and their related mechanism of action for overall AraC cytotoxicity.
引用
收藏
页码:388 / 393
页数:6
相关论文
共 30 条
[1]
Pyrimidine nucleotidases from human erythrocyte possess phosphotransferase activities specific for pyrimidine nucleotides [J].
Amici, A ;
Emanuelli, M ;
Magni, G ;
Raffaelli, N ;
Ruggieri, S .
FEBS LETTERS, 1997, 419 (2-3) :263-267
[2]
DNA repair mechanisms associated with cellular resistance to antitumor drugs: potential novel targets [J].
Barret, JM ;
Hill, BT .
ANTI-CANCER DRUGS, 1998, 9 (02) :105-123
[3]
The influence of 1-β-D-arabinofuranosylcytosine on the metabolism of phosphatidylcholine in human leukemic HL 60 and Raji cells [J].
Berkovic, D ;
Fleer, EAM ;
Breass, J ;
Pförtner, J ;
Schleyer, E ;
Hiddemann, W .
LEUKEMIA, 1997, 11 (12) :2079-2086
[4]
BHALLA K, 1991, EXP HEMATOL, V19, P669
[5]
BHALLA K, 1991, BLOOD, V78, P2674
[6]
Boogaerts MA, 1996, ANN ONCOL, V7, P1
[7]
Detection and determination of the major metabolites of [H-3]cytosine arabinoside by high-performance liquid chromatography [J].
Braess, J ;
Pfortner, J ;
Kaufmann, CC ;
Ramsauer, B ;
Unterhalt, M ;
Hiddemann, W ;
Schleyer, E .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 676 (01) :131-140
[8]
CHRESTA CM, 1996, BEHRING I MITT, V2, P232
[9]
DALY PF, 1990, CANCER RES, V50, P552
[10]
KINETIC-BEHAVIOR AND ALLOSTERIC REGULATION OF HUMAN DEOXYCYTIDYLATE DEAMINASE DERIVED FROM LEUKEMIC-CELLS [J].
ELLIMS, PH ;
KAO, AY ;
CHABNER, BA .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1983, 57 (02) :185-190